Melanoma Immunotherapy with GPR182 blockade
阻断 GPR182 的黑色素瘤免疫疗法
基本信息
- 批准号:10585749
- 负责人:
- 金额:$ 35.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-01-01 至 2027-12-31
- 项目状态:未结题
- 来源:
- 关键词:AblationBindingBiological AssayCD8-Positive T-LymphocytesCXCL10 geneCXCL9 geneCXCR3 geneCell TherapyCellsCharacteristicsClinicalEndocytosisEndothelial CellsEndotheliumExhibitsExtracellular MatrixG-Protein-Coupled ReceptorsGenerationsGeneticGlycosaminoglycansHomingHumanImageImmuneImmune responseImmunityImmunologic SensitizationImmunologicsImmunotherapyIn VitroInfiltrationInflammationInflammatoryInvestigationLeukocytesLigandsLymphaticLymphatic Endothelial CellsMalignant NeoplasmsModelingMolecularMonoclonal AntibodiesMusMutagenesisOrphanOutcomePathway interactionsPatientsPeptidesPlayPositioning AttributePre-Clinical ModelPublicationsRefractoryResearch ProposalsRoleStromal CellsT cell infiltrationT cell responseT-LymphocyteTechniquesTestingTherapeuticTissuesTumor Immunityanti-tumor immune responseantitumor effectcancer immunotherapycell motilitycheckpoint therapychemokinechemokine receptoreffector T cellimmune cell infiltrateimmune checkpoint blockadeimmune functionimmunoregulationimprovedin vivomelanomamigrationneoplasm immunotherapynovelnovel strategiesreceptorscavenger receptortargeted cancer therapytumortumor growthtumor microenvironmenttumor progressiontwo photon microscopy
项目摘要
Project Summary
Melanoma immunotherapy with GPR182 blockade
Immune checkpoint inhibitor therapy has greatly improved survival of patients with late-stage melanoma.
However, over half of patients do not benefit from this therapy. One of the main hurdles is that many melanoma
tissues lack effector CD8+ T cell infiltrates. Chemokines such as CXCL9 and CXCL10 play an important role in
regulating effector T cell infiltration into the tumors. Atypical Chemokine Receptors are a group of GPCR proteins
that are expressed in non-immune cells to actively regulate chemokines by endocytosis. Our studies uncovered
GPR182
as
a novel ACKR receptor selectively upregulated in peritumoral lymphatics. Our preliminary results
indicated that genetic deletion of this molecule in mice led to increased effector T cell infiltration and thereby the
retardment of tumor growth in several mouse melanoma models. We further found that GPR182 interacts with
chemokines broadly in vitro and blockade of CXCR3 completely abolished improved antitumor immunity in
GPR182- deficient mice. Here we hypothesize that GPR182 inhibits anti-tumor immune response by limiting
chemokine availability and targeting this pathway offers a novel approach to converting immunologically cold
melanoma to hot ones. We will dissect the molecular interaction between GPR182 and chemokines, and also
examine the chemokine endocytosis by GPR182 with tumors. The mechanisms by which GPR182 inhibits
antitumor T cell response will be investigated. Finally, the in vivo antitumor effect of a GPR182 monoclonal
antibody, which blocks the interaction between GPR182 and chemokines, will be assessed. By the completion
of these studies, we will identify a new strategy of inflaming immunologically cold melanoma and will have a
better understanding of the immunomodulatory role of the lymphatics in melanoma.
项目摘要
使用GPR182阻断的黑色素瘤免疫疗法
免疫检查点抑制剂治疗大大提高了晚期黑色素瘤患者的生存率。
然而,超过一半的患者没有从这种治疗中受益。主要障碍之一是许多黑色素瘤
组织缺乏效应CD8+ T细胞浸润。趋化因子如CXCL9和CXCL10在免疫调节中起重要作用。
调节效应T细胞向肿瘤中的浸润。非典型趋化因子受体是一组GPCR蛋白
在非免疫细胞中表达,通过内吞作用积极调节趋化因子。我们的研究发现
GPR182
作为
一种新的在瘤周肿瘤中选择性上调的ACKR受体。我们的初步结果
表明小鼠中该分子的遗传缺失导致效应T细胞浸润增加,从而导致免疫缺陷。
在几种小鼠黑色素瘤模型中肿瘤生长的延迟。我们进一步发现GPR182与
CXCR3的阻断完全消除了体外培养中提高的抗肿瘤免疫力。
GPR182缺陷小鼠。在这里,我们假设GPR182通过限制抗肿瘤免疫反应来抑制抗肿瘤免疫反应
趋化因子的可用性和靶向这一途径提供了一种新的方法,
从黑色素瘤到性感的我们将剖析GPR182和趋化因子之间的分子相互作用,
用GPR182检测肿瘤细胞对趋化因子的内吞作用。GPR182抑制的机制
将研究抗肿瘤T细胞应答。最后,研究了GPR182单克隆抗体的体内抗肿瘤作用。
将评估阻断GPR182和趋化因子之间相互作用的抗体。通过完成
在这些研究中,我们将确定一种新的免疫性冷黑色素瘤炎症策略,
更好地理解免疫调节剂在黑色素瘤中的作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yuwen Zhu其他文献
Yuwen Zhu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yuwen Zhu', 18)}}的其他基金
The GPR171 pathway in cancer immunotherapy
癌症免疫治疗中的 GPR171 通路
- 批准号:
10635418 - 财政年份:2023
- 资助金额:
$ 35.57万 - 项目类别:
相似国自然基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:32170319
- 批准年份:2021
- 资助金额:58.00 万元
- 项目类别:面上项目
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
- 批准号:31672538
- 批准年份:2016
- 资助金额:62.0 万元
- 项目类别:面上项目
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
- 批准号:31372080
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
- 批准号:81172529
- 批准年份:2011
- 资助金额:58.0 万元
- 项目类别:面上项目
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
- 批准号:81070952
- 批准年份:2010
- 资助金额:35.0 万元
- 项目类别:面上项目
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
- 批准号:30672361
- 批准年份:2006
- 资助金额:24.0 万元
- 项目类别:面上项目
相似海外基金
Collaborative Research: NSF-BSF: How cell adhesion molecules control neuronal circuit wiring: Binding affinities, binding availability and sub-cellular localization
合作研究:NSF-BSF:细胞粘附分子如何控制神经元电路布线:结合亲和力、结合可用性和亚细胞定位
- 批准号:
2321481 - 财政年份:2024
- 资助金额:
$ 35.57万 - 项目类别:
Continuing Grant
Collaborative Research: NSF-BSF: How cell adhesion molecules control neuronal circuit wiring: Binding affinities, binding availability and sub-cellular localization
合作研究:NSF-BSF:细胞粘附分子如何控制神经元电路布线:结合亲和力、结合可用性和亚细胞定位
- 批准号:
2321480 - 财政年份:2024
- 资助金额:
$ 35.57万 - 项目类别:
Continuing Grant
Postdoctoral Fellowship: OPP-PRF: Understanding the Role of Specific Iron-binding Organic Ligands in Governing Iron Biogeochemistry in the Southern Ocean
博士后奖学金:OPP-PRF:了解特定铁结合有机配体在控制南大洋铁生物地球化学中的作用
- 批准号:
2317664 - 财政年份:2024
- 资助金额:
$ 35.57万 - 项目类别:
Standard Grant
Conformations of musk odorants and their binding to human musk receptors
麝香气味剂的构象及其与人类麝香受体的结合
- 批准号:
EP/X039420/1 - 财政年份:2024
- 资助金额:
$ 35.57万 - 项目类别:
Research Grant
NPBactID - Differential binding of peptoid functionalized nanoparticles to bacteria for identifying specific strains
NPBactID - 类肽功能化纳米粒子与细菌的差异结合,用于识别特定菌株
- 批准号:
EP/Y029542/1 - 财政年份:2024
- 资助金额:
$ 35.57万 - 项目类别:
Fellowship
Alkane transformations through binding to metals
通过与金属结合进行烷烃转化
- 批准号:
DP240103289 - 财政年份:2024
- 资助金额:
$ 35.57万 - 项目类别:
Discovery Projects
I-Corps: Translation Potential of Real-time, Ultrasensitive Electrical Transduction of Biological Binding Events for Pathogen and Disease Detection
I-Corps:生物结合事件的实时、超灵敏电转导在病原体和疾病检测中的转化潜力
- 批准号:
2419915 - 财政年份:2024
- 资助金额:
$ 35.57万 - 项目类别:
Standard Grant
The roles of a universally conserved DNA-and RNA-binding domain in controlling MRSA virulence and antibiotic resistance
普遍保守的 DNA 和 RNA 结合域在控制 MRSA 毒力和抗生素耐药性中的作用
- 批准号:
MR/Y013131/1 - 财政年份:2024
- 资助金额:
$ 35.57万 - 项目类别:
Research Grant
CRII: OAC: Development of a modular framework for the modeling of peptide and protein binding to membranes
CRII:OAC:开发用于模拟肽和蛋白质与膜结合的模块化框架
- 批准号:
2347997 - 财政年份:2024
- 资助金额:
$ 35.57万 - 项目类别:
Standard Grant
How lipid binding proteins shape the activity of nuclear hormone receptors
脂质结合蛋白如何影响核激素受体的活性
- 批准号:
DP240103141 - 财政年份:2024
- 资助金额:
$ 35.57万 - 项目类别:
Discovery Projects